Literature DB >> 9743230

Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.

G Chiesa1, C Parolini, M Canavesi, N Colombo, C R Sirtori, R Fumagalli, G Franceschini, F Bernini.   

Abstract

The first step in reverse cholesterol transport is the movement of cholesterol out of cells onto lipoprotein acceptors in the interstitial fluid. The contribution of specific lipoprotein components to this process remains to be established. In this study, the role of human apolipoproteins (apo) A-I and A-II in the efflux of cellular cholesterol was investigated in transgenic mouse models in which the expression of murine apoA-I was abolished due to gene targeting (A-IKO). Serum from A-IKO mice and from mice expressing human apoA-I and/or human apoA-II was incubated with [3H]cholesterol-labeled Fu5AH rat hepatoma cells for 4 hours at 37 degrees C. The cholesterol efflux to the serum of A-IKO mice was markedly lower than that to the serum of mice transgenic for human apoA-I (5.0 +/- 1.5% versus 25.0 +/- 4.0%). Expression of human apoA-II alone did not modify the cholesterol efflux capacity of A-IKO mouse serum. Cholesterol efflux to serum of mice expressing human apoA-II together with human apoA-I was significantly lower than that to human apoA-I mouse serum (20.0 +/- 2.3% versus 25.0 +/- 4.0%). Regression analysis of cholesterol efflux versus the lipid/apolipoprotein concentrations of mouse serum suggested that 3 independent factors contribute to determine the cholesterol efflux potential of serum: the apolipoprotein composition of HDL, the serum concentration of HDL phospholipids, and the presence of a small fraction of particles containing apoA-I.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743230     DOI: 10.1161/01.atv.18.9.1417

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease.

Authors:  Cinzia Marchi; Maria Pia Adorni; Paolo Caffarra; Nicoletta Ronda; Marco Spallazzi; Federica Barocco; Daniela Galimberti; Franco Bernini; Francesca Zimetti
Journal:  J Lipid Res       Date:  2019-06-05       Impact factor: 5.922

2.  Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL.

Authors:  Marta Marchesi; Cinzia Parolini; Silvia Caligari; Donatella Gilio; Stefano Manzini; Marco Busnelli; Paola Cinquanta; Marina Camera; Marta Brambilla; Cesare R Sirtori; Giulia Chiesa
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

3.  Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.

Authors:  S Pierno; M P Didonna; V Cippone; A De Luca; M Pisoni; A Frigeri; G P Nicchia; M Svelto; G Chiesa; C Sirtori; E Scanziani; C Rizzo; D De Vito; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

4.  APOA2 Polymorphism in Relation to Obesity and Lipid Metabolism.

Authors:  Moushira Erfan Zaki; Khalda Sayed Amr; Mohamed Abdel-Hamid
Journal:  Cholesterol       Date:  2013-12-09

5.  Evaluating the association of APOA2 polymorphism with insulin resistance in adolescents.

Authors:  Moushira Erfan Zaki; Khalda Sayed Amr; Mohamed Abdel-Hamid
Journal:  Meta Gene       Date:  2014-05-15

6.  New Strategies to Promote Macrophage Cholesterol Efflux.

Authors:  Hong Y Choi; Isabelle Ruel; Shiwon Choi; Jacques Genest
Journal:  Front Cardiovasc Med       Date:  2021-12-23

7.  Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice.

Authors:  S Manzini; C Pinna; M Busnelli; P Cinquanta; E Rigamonti; G S Ganzetti; F Dellera; A Sala; L Calabresi; G Franceschini; C Parolini; G Chiesa
Journal:  Vascul Pharmacol       Date:  2015-08-05       Impact factor: 5.773

Review 8.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.